The firms plan to integrate Curetis' Unyvero sample prep system and MGI's NGS to create a microbial pathogens and antibiotic resistance detection workflow.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The partners plan to apply genomics to traditional Chinese medicine.
The researchers said that better diagnostics are needed to distinguish between false preterm labor and true preterm labor to prevent unnecessary treatment.
The partners are initially planning to make searchable whole-genome data and EMRs from more than 1,000 rheumatoid arthritis patients accessible to trial developers.
The partners will use Hummingbird's miRNA database and expertise in sample preparation as well as BGI's BGISEQ sequencer and analysis pipeline to develop targeted miRNA IVD assays.
The funding is being provided by Genome Canada, as well as various Canadian provinces, businesses, and research institutes.
BGI is also developing sequencing-based self-sampling assays for pharmacogenomics and hereditary cancer testing.
The company recently released the MGISEQ-2000, MGISEQ-200, and MGIFLP sequencing platforms, as well as the MGIUS-R3 robotic ultrasound system.
The new agreement between the two companies commits to expanding the clinical genetic testing market in Turkey and is part of a global expansion for BGI.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.